This proforma models the outpatient Cancer Center contract at full production. The incoming physician begins as an inpatient oncology hospitalist at Piermont Hospital under a separate contract, then transitions into the main outpatient group. The base salary of $480,000 sits between the MGMA 50th and 75th percentiles for total compensation in this specialty, providing a solid income floor. However, the incentive threshold as calculated from the base and conversion factor is 24,000 wRVUs, which is more than double the MGMA 90th percentile for this specialty (11,555 wRVUs). In practical terms, incentive compensation is not attainable at any typical production level. The base salary is effectively the total compensation for this role as structured. This is a significant structural concern and should be reviewed with the client before the position is marketed.
*This model includes assumed and/or estimated inputs where data was not provided. Assumptions are clearly marked. Final compensation details are to be confirmed by the employer.
| Variable | Value |
|---|---|
| Clinical Days per Week | 4* |
| Clinical Hours per Week | 32* |
| Patients per Day | 25* |
| Weeks Worked | 46* |
| Base Salary | $480,000 |
| Conversion Factor | $20.00 per wRVU |
| Incentive Threshold | 24,000 wRVUs* (Base ÷ CF = $480,000 ÷ $20) |
| wRVU per Visit | 1.47* (MGMA median wRVUs ÷ estimated annual visits) |
| Signing Bonus | $25,000 |
Note: HemOnc wRVU production is substantially augmented by infusion and chemotherapy administration codes beyond standard E&M visits. Even accounting for infusion volume, the MGMA 90th percentile for this specialty is 11,555 wRVUs nationally. The threshold of 24,000 wRVUs is not achievable at any documented production level for this specialty.
Annual Visits = Clinical Days × Patients per Day × Weeks Worked
| Variable | Formula | Value |
|---|---|---|
| Annual Visits | 4 × 25 × 46 | 4,600* |
| Total wRVUs (Assumed Schedule) | 4,600 × 1.47 | 6,762* |
| Total wRVUs (MGMA Median) | MGMA HemOnc General Overall | 6,393* |
| Total wRVUs (MGMA 75th) | MGMA HemOnc General Overall | 8,564* |
| Total wRVUs (MGMA 90th) | MGMA HemOnc General Overall | 11,555* |
Incentive Compensation = (Total wRVUs − Threshold) × Conversion Factor
Total Compensation = Base Salary + Incentive Compensation
Base: $480,000 | Threshold: 24,000 wRVUs | CF: $20.00*
| Scenario | Total wRVUs | Incentive | Total Compensation |
|---|---|---|---|
| MGMA Median | 6,393* | $0 (below threshold) | $480,000 |
| MGMA 75th | 8,564* | $0 (below threshold) | $480,000 |
| MGMA 90th | 11,555* | $0 (below threshold) | $480,000 |
| Metric | Calculated Value | MGMA Percentile | Interpretation |
|---|---|---|---|
| Total Compensation (Base) | $480,000 | 50th–75th* | Market-Aligned Compensation on base salary alone |
| wRVU Productivity, MGMA Median | 6,393* | 50th* | MGMA HemOnc General Overall |
| Incentive Threshold | 24,000 wRVUs* | Above 90th* | Threshold is more than double the MGMA 90th percentile (11,555*); incentive compensation is not attainable at any typical production level; client review strongly recommended |
| Pay per wRVU at Median Production | $75.08* | 50th* | Compensation per wRVU at median production is below MGMA median ($98.56*) due to low conversion factor |
MGMA Source: Hematology/Oncology, General, Overall, 2025 MGMA DataDive
wRVU Percentiles: 10th: 3,062 | 25th: 4,574 | Median: 6,393 | 75th: 8,564 | 90th: 11,555
Compensation Percentiles: 10th: $351,675 | 25th: $469,122 | Median: $589,102 | 75th: $751,547 | 90th: $963,846
| Year | Role | wRVUs | Total Compensation |
|---|---|---|---|
| Year 1 | Inpatient Hospitalist, Piermont Hospital | Per inpatient contract* | Per inpatient contract (details to be confirmed) |
| Year 2, Full Production | Outpatient Cancer Center, MGMA Median | 6,393* | $480,000* |
| Year 3 | Outpatient Cancer Center | 6,585* | $494,400* (Year 2 × 1.03) |
| Variable | Value |
|---|---|
| Coverage Type | Occurrence or claims-made with tail* |
| Coverage Limits | $1M / $3M* (standard Louisiana) |
| Source | Not confirmed; to be verified with client |
Willis-Knighton provides the following benefits and financial incentives not reflected in the production model above.